Clinical Trial Update: HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab [Phase 2]

View source ↗

Summary

Phase 2 trial results for HuMax-CD20 (ofatumumab) in rituximab-refractory follicular lymphoma are reported. The study has completed and results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• HuMax-CD20 (ofatumumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Follicular | Phase 2 | Status: COMPLETED | Results posted: 2011-12-08